Healthy Male Subjects Clinical Trial
Official title:
Bioequivalence Study of Tafolecimab Injections Manufactured by Two Different Processes in Chinese Healthy Male Volunteers
Verified date | April 2023 |
Source | Innovent Biologics (Suzhou) Co. Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is conducted in China. The purpose of this study is to evaluate the pharmacokinetic similarity of Tafolecimab with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of sintilimab with different manufacturing process,also to determine Pharmacodynamics of Tafolecimab with different manufacturing process
Status | Completed |
Enrollment | 166 |
Est. completion date | August 4, 2023 |
Est. primary completion date | March 26, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Male subjects between 18 and 65 years of age, inclusive. 2. Low-density lipoprotein cholesterol (LDL-C) within the range of 1.8 mmol/L to 4.9 mmol/L, inclusive, at screening. 3. Body weight within the range of 63.0 kilograms (kg) to 75.0 kg, inclusive. 4. Subjects who are willing maintain current normal diet and physical activity. 5. Subjects agree to use reliable contraceptive measures (such as abstinence, sterilization, contraceptives, injectable contraceptive medroxyprogesterone or subcutaneous implant contraception, etc.) during the study period and within 6 months after the study drug infusion. 6. No history of serious diseases, including (but not limited to) cardiovascular, hepatic, renal, gastrointestinal, psychiatric, neurologic, endocrine, pulmonary, hematological, immune disease. 7. Subjects voluntarily signed the informed consent form and agreed to strictly follow the requirements of this protocol. Exclusion Criteria: 1. Subjects who have a history of allergy, or may be allergic to the investigational drug and the related compounds. 2. Have used the inhibitors of proprotein convertase subtilisin type 9 (PCSK-9). 3. Have clinically relevant abnormalities identified by Vital signs, physical examination, clinical laboratory tests, 12-lead ECG, or chest X-ray, at screening. 4. Unwilling to stop any strenuous physical activity (such as weightlifting or long-distance running) within 72 hours before the planned follow-up visit. 5. History of hospitalization within 1 month before screening, major surgery within 6 months before screening, or other unstable conditions judged by the investigator. 6. The last dose of the previous investigational product which is chemical drug has been given in less than 1 month before administration. 7. The last dose of the previous investigational product which is biological drug has been given in less than 3 months before administration. 8. Have used any drugs (including over-the-counter drugs or prescription drugs), the last medication is less than 14 days or the last medication is less than 5 half-lives of the drug from the administration day (whichever is longer), or are using any drugs. 9. Have used any traditional Chinese medicines, vitamins or drugs or supplements known to affect lipid metabolism within 30 days before administration. 10. Have a positive test result of human immunodeficiency virus (Human Immunodeficiency Virus, HIV) antibody, hepatitis B virus surface antigen (HBsAg), Hepatitis C virus (HCV) antibody or syphilis test at screening. 11. History of alcohol or drug abuse results within 12 months before screening. Average daily alcohol intake is more than 3 units of alcohol (male) (1 unit˜360mL beer, or 45mL spirits with 40% alcohol content, or 150mL wine), or unwilling to stop drinking 72 hours before administration and throughout the study period, or a positive ethanol breath test at screening, or positive drug screening results by urine at screening. 12. unable to abstain from smoking, alcohol and caffeinated beverages within 72 hours before administration and throughout the study period. 13. lost blood, donated blood =200 ml within 2 months before screening. 14. History of organ transplantation or malignant tumor. 15. Not suitable for this study in the investigator's opinion. |
Country | Name | City | State |
---|---|---|---|
China | Aerospace Center Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Innovent Biologics (Suzhou) Co. Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bioequivalence results using the peak serum drug concentration (Cmax) as the judging indicators | up to Day 57 | ||
Primary | Bioequivalence results using the area under the serum concentration-time curve (AUC0-inf) as the judging indicators | up to Day 57 | ||
Secondary | Other PK parameters: Area under the plasma concentration-time curve (AUClast) | up to Day 57 | ||
Secondary | Other PK parameters: Volume of distribution (V) | up to Day 57 | ||
Secondary | Other PK parameters: elimination half-life (t1/2) | up to Day 57 | ||
Secondary | Number of participants with adverse events, with abnormal vital signs, abnormal physical examination, abnormal laboratory test results and abnormal ECG readings | up to Day 57 | ||
Secondary | The occurrence of Anti-drug Antibody(ADA) | up to Day 57 | ||
Secondary | The occurrence of Neutralizing antibodies Antibody(NAb) | up to Day 57 | ||
Secondary | Percentage Change from baseline in Low Density Lipoprotein choleterol (LDL-C) | up to Day 57 | ||
Secondary | Percentage Change from baseline in Proprotein convertase subtilisin/kexin type 9(PCSK-9) | up to Day 57 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05621447 -
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
|
Phase 1 | |
Completed |
NCT02901366 -
Mass Balance Study of FYU-981
|
Phase 2 | |
Not yet recruiting |
NCT01928563 -
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine
|
Phase 1 | |
Completed |
NCT05559554 -
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
|
Phase 1 | |
Completed |
NCT04512872 -
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT06111196 -
Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT03317652 -
Effect of Sodium Nitroprusside on Cerebral Blood Flow
|
N/A | |
Completed |
NCT04655872 -
Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02609711 -
Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects
|
Phase 1 | |
Withdrawn |
NCT02560363 -
A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT01261260 -
Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05072028 -
Mass Balance and Biotransformation Study of [14C]DBPR108 in Human
|
Phase 1 | |
Completed |
NCT05446233 -
ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT05275010 -
A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System
|
Phase 1 | |
Completed |
NCT04839744 -
A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT03576651 -
A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT04825431 -
Mass Balance Study of [14C] TAS-205 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01819779 -
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)
|
Phase 1 | |
Completed |
NCT05126784 -
AVT03 With Prolia in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT04850638 -
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
|
Phase 1 |